Skip to content

Buprenorphine following ketamine treatment enhances anti‐suicidal effects

The Brown University Psychopharmacology Update September 1, 2026 DOI: 10.1002/pu.31484 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Population Patients with major depressive disorder (MDD)
Interventions Ketamine Buprenorphine
Duration 4 weeks of buprenorphine treatment following a single ketamine infusion
Topics Esketamine Ketamine
Key findings Buprenorphine following a single ketamine infusion significantly reduced suicidal ideation compared with ketamine plus placebo over four weeks, with no serious treatment-related adverse events.

Abstract

Patients with major depressive disorder (MDD) who received 4 weeks of buprenorphine treatment following a single infusion of ketamine experienced a significant reduction in suicidal ideation compared with ketamine plus placebo, a randomized, double‐blind trial has found. No serious treatment‐related adverse events were reported. Study results were published online May 19, 2026 in the American Journal of Psychiatry .

Related reading